Critical Path Institute (C-Path), a number one global nonprofit committed to expediting drug development through the acceleration of regulatory-endorsed solutions, today announced a newly formalized Memorandum of Understanding (MOU) with Vivpro, an industry-leading provider of a revolutionary biointelligence software platform and progressive services. The partnership will enhance C-Path’s core competencies in accelerating drug development, by utilizing advanced data analytics and deep machine learning insights offered by Vivpro to further revolutionize regulatory strategy and intelligence.

As a part of this collaboration, the VivproAI platform will likely be deployed to constantly monitor and quantify C-Path’s impact on accelerating and reworking drug development. The platform can even function a critical tool to constantly inform the regulatory strategies of varied public-private partnerships coordinated by C-Path.

C-Path’s established expertise in data management and standards, biomarkers, modeling and analytics, regulatory science, and clinical final result assessments will complement Vivpro’s progressive technology. Together, they aim to supply regulatory-grade solutions that advance the event of medical products.

Collaborating with Vivpro will significantly enhance our capability to observe and quantify the impact that solutions for drug development, generated through C-Path’s public-private partnerships, have had in transforming the drug development landscape across many therapeutic areas. This partnership aligns seamlessly with our mission of accelerating the efficiency of the event process for progressive medical treatments.”

Klaus Romero, M.D., M.S., F.C.P., C-Path’s Chief Science Officer and Executive Director of Clinical Pharmacology

Pravin Jadhav, B.Pharm., M.Pharm., Ph.D., MPH, CEO of Vivpro, stated, “It’s exciting to partner with C-Path in a latest capability. This partnership allows us to mix our AI-driven regulatory strategy and intelligence capabilities with their domain expertise. Together, we hope to reshape the regulatory strategy and intelligence. The collaboration will foster scientific and skilled synergy to speed up the event of secure and effective medical products.”

The MOU also outlines a shared commitment to explore potential funding opportunities to strengthen this collaboration further. Each parties have pledged to support scientific and skilled activities and to co-sponsor workshops and courses aimed toward training scientists in the sector of drug development and regulatory science.

As well as, C-Path and Vivpro will provide opportunities for scientists and staff from each organizations to collaborate on specific projects. This initiative will cultivate a collaborative environment conducive to knowledge sharing, potentially resulting in scientific advancements in areas of mutual interest.

Source:

Critical Path Institute (C-Path)